Durata Therapeutics (NASDAQ:DRTX)

CAPS Rating: 2 out of 5

Results 1 - 4 of 4

Recs

0
Member Avatar jackspicks (< 20) Submitted: 5/24/2014 2:16:53 PM : Outperform Start Price: $16.07 DRTX Score: +41.77

drtx

Recs

0
Member Avatar tsaifool (91.16) Submitted: 2/21/2014 2:38:51 PM : Outperform Start Price: $14.02 DRTX Score: +59.68

bought rights to Dalbavancin which is a once weekly injectable, if marketed correctly, could be a nice transition drug from inpt to outpt therapy, would be also useful in an OPIC/OPAT setting, hopefully it is finally approved after 10 years in a rut

Recs

0
Member Avatar simonwmich (< 20) Submitted: 1/18/2014 5:42:02 PM : Outperform Start Price: $12.76 DRTX Score: +77.04

As we enter into the era of hospital performance based reimbursement, any drug that keeps patients from being readmitted will be very attractive to hospitals. The once/week treatment also guarantees compliance vs oral meds.

Recs

0
Member Avatar line70day (< 20) Submitted: 12/1/2013 2:30:42 PM : Outperform Start Price: $11.63 DRTX Score: +93.02

A biopharmaceutical Co. devoloping therapies to treat infectous diseases and illnesses jumped 20% after acceptance of drug Dalvance for prior review by FDA

Results 1 - 4 of 4

Featured Broker Partners


Advertisement